论文部分内容阅读
随着全球肥胖的流行,肥胖、2型糖尿病和高血压,使心血管事件的发生时间越来越早。糖尿病是重大的公共卫生问题,需要对其和相关并发症进行更积极的管理,特别是心血管疾病。已知内皮细胞功能紊乱在代谢综合征或胰岛素抵抗的最初阶段就存在,也许还包括2型糖尿病发生的最初几年。目前,对于糖尿病患者的CVD管理,大家都把重点放在血管内皮细胞功能上,并把它作为药物治疗的潜在靶点,当然,这里不包括所有的处方药。基于此,我们调查了6类目前常用的、以内皮细胞为靶点的降压药;另外,我们还建议开发以内皮细胞为靶点的新药,这些新药能够修复损伤的内皮细胞和提高一氧化氮的生物利用率,以预防心血管事件。
With the global epidemic of obesity, obesity, type 2 diabetes and hypertension, cardiovascular events occur sooner and later. Diabetes is a major public health problem that requires more aggressive management of it and its associated complications, particularly cardiovascular disease. It is known that endothelial dysfunction occurs at the initial stages of metabolic syndrome or insulin resistance and may also include the first few years in which type 2 diabetes occurs. At present, for the CVD management of diabetic patients, everybody focuses on the function of the vascular endothelial cells and uses it as a potential target for drug treatment. Of course, not all prescription drugs are included here. Based on this, we investigated six currently used antihypertensive drugs targeting endothelial cells. In addition, we also recommend the development of new drugs targeting endothelial cells that repair damaged endothelial cells and enhance the oxidation of monocytes Bioavailability of nitrogen to prevent cardiovascular events.